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Abstract: Hepatitis C virus (HCV) is a causative agent of acute and chronic hepatitis, 
leading to the development of hepatic cirrhosis and hepatocellular carcinoma. We prepared 
extracts from 61 marine organisms and screened them by an in vitro fluorescence assay 
targeting the viral helicase (NS3), which plays an important role in HCV replication, to 
identify effective candidates for anti-HCV agents. An ethyl acetate-soluble fraction of the 
feather star Alloeocomatella polycladia exhibited the strongest inhibition of NS3 helicase 
activity, with an IC50 of 11.7 µg/mL. The extract of A. polycladia inhibited interaction 
between NS3 and RNA but not ATPase of NS3. Furthermore, the replication of the 
replicons derived from three HCV strains of genotype 1b in cultured cells was suppressed 
by the extract with an EC50 value of 23 to 44 µg/mL, which is similar to the IC50 value of 
the NS3 helicase assay. The extract did not induce interferon or inhibit cell growth. These 
results suggest that the unknown compound(s) included in A. polycladia can inhibit HCV 
replication by suppressing the helicase activity of HCV NS3. This study may present a new 
approach toward the development of a novel therapy for chronic hepatitis C. 
Keywords: marine organism; Alloeocomatella polycladia; hepatitis C virus; NS3 helicase 
 
1. Introduction 
Hepatitis C virus (HCV) is an etiological agent of liver disease including steatosis, cirrhosis, and 
hepatocellular carcinoma, and has infected over 170 million individuals worldwide [1,2]. HCV belongs 
to the genus Hepacivirus of the Flaviviridae family. The genome of HCV is a single positive-strand 
RNA composed of 9.6 kb flanked by 5' and 3'-untranscribed regions (UTRs) and encodes a polyprotein 
consisting of approximately 3000 amino acids [3]. The polyprotein is translated from a viral genome 
by an internal ribosome entry site (IRES), which is localized in 5'-UTR [4]. The translated polyprotein 
is cleaved by host and viral proteases into 10 proteins. The structural proteins consisting of core, E1, 
and E2 and a viroporin p7, which has not yet been classified as either a structural or nonstructural 
protein, are located in the N-terminal quarter of the polyprotein. The nonstructural proteins including Mar. Drugs 2012, 10               
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NS2, NS3, NS4A, NS4B, NS5A, and NS5B occupy the remaining portion of the polyprotein and form 
a replication complex with several host factors. 
HCV NS3 is well known to play a crucial role in viral replication because it possesses helicase and 
protease activities [5,6]. The N-terminal third of NS3 forms a complex with the NS4A protein and 
exhibits serine protease activity (NS3-4A protease) to cleave the viral polyprotein for the maturation of 
viral proteins [7]. The remaining portion of NS3 occupies the RNA helicase domain, characterized by 
the activities of ATPase and RNA binding, both of which contribute to the unwinding of duplex 
RNA [8,9]. The helicase activity is needed to separate duplex RNA during viral RNA replication [10]. 
A negative-strand RNA is synthesized based on a viral genome (positive strand) after the uncoating of 
a viral particle in the infected cells and then is itself used as a template to synthesize a positive-strand 
RNA packaged into the viral particle. Thus, helicase as well as protease activities of NS3 can be 
targeted for use in the development of antiviral agents against HCV. 
The current therapy, which combines pegylated interferon with ribavirin, is effective in only about 
half of patients infected with the most common genotype worldwide, genotype 1 [11–13]. However, 
this therapy has side effects including influenza-like symptoms, cytopenias, and depression [11]. 
Furthermore, no effective vaccines for HCV have been developed yet. Biotechnological advances of 
the past decade have led to the development of novel therapies using anti-HCV agents that directly 
target HCV proteins or host factors required for HCV replication. This approach has been named either 
“specifically targeted antiviral therapy for hepatitis C” (STAT-C) or “directed-acting antiviral agents” 
(DAA) [14–16]. Several compounds of STAT-C or DAA have proceeded to clinical trials. Telaprevir 
and boceprevir, which are categorized as advanced NS3/4A protease inhibitors, were recently 
approved for the treatment of chronic hepatitis C patients infected with genotype 1 in the US, EU, 
Canada, and Japan [17,18]. However, the emergence of drug-resistant viruses is the major problem for 
therapies using antiviral compounds [19,20]. Accordingly, several kinds of drugs targeting various 
molecules or positions will be required for the complete eradication of the virus from hepatitis C patients. 
The helicase activity of NS3 could be targeted by development of anti-HCV compound in addition 
to its protease activity. Belon et al. reported that 1-N,4-N-bis[4-(1H-benzimidazol-2-yl)phenyl] 
benzene-1,4-dicarboxamine, designated as (BIP)2B, is a potent and selective inhibitor of HCV NS3 
helicase [21]. (BIP)2B could not affect ATP hydrolysis without RNA or at a saturated concentration of 
RNA. QU663 inhibits the unwinding activity of NS3 helicase by binding to the RNA-binding groove 
irrespective of its own ATPase activity [22]. Compound QU663 may competitively bind the RNA-binding 
site of NS3 but not affect ATPase activity, resulting in the inhibition of unwinding activity. 
Various drugs have been generated from natural products, especially those from terrestrial plants 
and microbes. The development of drugs from natural products has declined in the past two decades by 
the emergence of high-throughput screening of synthetic chemical libraries. However, recent technical 
advances in the determination of molecular structures and in the synthesis of chemical compounds 
have raised awareness about natural products as a resource for drug development [23–25]. Several 
groups recently reported natural products that inhibit HCV replication in vitro. For instance, silbinin, 
which is identified from the milk thistle [26,27], epigallocatechin 3-gallate, which is from green tea [28], 
and proanthocyanidins, which are from blueberry leaves [29], can inhibit HCV replication in cultured 
cells. Marine organisms including plants and animals were recently established as a representative 
natural resource library for drug development, since there are estimated to be more than 300,000 Mar. Drugs 2012, 10               
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species of marine organisms. The products isolated from the marine organisms often possess potent 
biological activities corresponding to the organisms’ own novel molecular structures. Thus, marine 
natural products are considered to include highly significant lead compounds for drug 
development [30,31]. For example, trabectedin (Yondelis), cytarabine (Ara-C), and eribulin (Halaven) 
are approved anticancer drugs developed from marine organisms [32]. However, marine organisms 
have not yet been screened for development into anti-HCV agents. 
In this study, we screened extracts of marine organisms by using an in vitro fluorescence NS3 
helicase assay and HCV replicon system to find candidates for safe and effective anti-HCV agents. 
The marine feather star Alloeocomatella polycladia may produce anti-HCV helicase agents that 
suppress HCV replication. 
2. Results and Discussion 
2.1. Primary Screening of Marine Organism Extracts on HCV NS3 Helicase Activity 
We employed high-throughput screening using a photoinduced electron transfer (PET) assay to 
identify inhibitors of HCV NS3 helicase activity from extracts of marine organisms (Figure 1). The 
EtOAc- and MeOH-soluble extracts were prepared from marine organisms obtained from the sea 
around Okinawa Prefecture, Japan. We identified 16 extracts possessing an arbitrary level of inhibitory 
activity, which is defined as below 60% of the control in this study (Table 1). Five extracts exhibited 
high inhibition levels (<30%), and eleven extracts exhibited intermediate inhibition levels (30% to 
60%). The EtOAc extract prepared from the feather star Alloeocomatella polycladia (Figure 2) 
exhibited the strongest inhibitory activity among them, and was designated SG1-23-1 in this study. 
Treatment with SG1-23-1 inhibited the helicase activity in a dose-dependent manner (Figure 3A). The 
value of IC50 is calculated as 11.7 ± 0.7 µg/mL. We confirmed the effect of SG1-23-1 on NS3 helicase 
unwinding activity by the RNA helicase assay using 
32P-labeled double-stranded RNA (dsRNA) as a 
substrate. Treatment with SG1-23-1 inhibited dsRNA dissociation at concentrations of 16 µg/mL and 
above (Figure 3B). These results suggest that treatment with SG1-23-1 inhibits the unwinding ability 
of HCV NS3 helicase. 
Table 1. Inhibitory effects of marine organism extracts on hepatitis C virus (HCV) NS3 
helicase activity. 
   Helicase 
Activity 
(% of control) 
               
Sample Specimen  Phylum  Extract  Collection  Site 
OK-99-2 78  Agelas sp.  Porifera EtOAc  Shimoji  Island 
OK-99-3 73  Plakortis sp.  Porifera EtOAc  Shimoji  Island 
OK-99-4 60  Dysidea arenaria  Porifera EtOAc  Shimoji  Island 
OK-99-5 96  Theonella cupola  Porifera EtOAc  Shimoji  Island 
OK-99-6 52  Theonella conica  Porifera EtOAc  Shimoji  Island 
OK-99-7 85  Epipolasis kushimotoensis  Porifera EtOAc  Shimoji  Island 
OK-99-9 51  Hyrtios sp.  Porifera EtOAc  Shimoji  Island Mar. Drugs 2012, 10               
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Table 1. Cont. 
OK-99-10 75  Theonella sp.  Porifera EtOAc  Shimoji  Island 
OK-99-12 53  Isis hippuris  Cnidaria EtOAc  Shimoji  Island 
OK-99-13 68  Acanthella sp.  Porifera EtOAc  Shimoji  Island 
OK-99-15 64  Phyllospongia sp.  Porifera EtOAc  Shimoji  Island 
OK-99-17 59  Petrosia sp.  Porifera EtOAc  Shimoji  Island 
OK-99-18 80  Fasciospongia rimosa  Porifera EtOAc  Shimoji  Island 
OK-99-20 77  Echinoclathria sp.   Porifera EtOAc  Shimoji  Island 
OK-99-21 68  Strongylophora sp.  Porifera EtOAc  Shimoji  Island 
OK-99-23 74  Dysidea herbacea  Porifera EtOAc  Shimoji  Island 
OK-99-26 55  Dysidea cf. arenaria  Porifera EtOAc  Shimoji  Island 
OK-99-28 123  Plakortis sp.  Porifera EtOAc  Shimoji  Island 
OK-99-31 118  Spongia sp.   Porifera EtOAc  Okinawa  Island 
OK-99-34 119  Theonella swinhoei  Porifera EtOAc  Okinawa  Island 
OK-99-35 108  Petrosia sp.  Porifera EtOAc  Okinawa  Island 
OK-99-36 90  Acanthella sp.  Porifera EtOAc  Okinawa  Island 
OK-99-37 102  Luffariella sp.  Porifera EtOAc  Okinawa  Island 
OK-99-41 62  Dysidea cf. arenaria  Porifera EtOAc  Okinawa  Island 
OK-99-43 85  Xestospongia sp.  Porifera EtOAc  Okinawa  Island 
OK-99-44 61  Dysidea arenaria  Porifera EtOAc  Okinawa  Island 
OK-99-47 108  Dysidea cf. arenaria  Porifera EtOAc  Okinawa  Island 
OK-99-49 90  Petrosia sp.  Porifera EtOAc  Chibishi   
OK-99-51 69  Isis hippuris  Cnidaria EtOAc  Chibishi   
OK-99-52 78  Petrosia sp.  Porifera EtOAc  Kuro  Island 
OK-99-55 65  Acanthella sp.  Porifera EtOAc  Kuro  Island 
OK-99-57 84  Theonella swinhoei  Porifera EtOAc  Kuro  Island 
OK-99-63 117  Epipolasis kushimotoensis  Porifera EtOAc  Kuro  Island 
OK-99-64 98  Xestospongia sp.  Porifera EtOAc  Kuro  Island 
SG1-1-2 77  Comanthus gisleni  Echinodermata MeOH  Kume  Island 
SG1-2-2 112  Stephanometra indica  Echinodermata MeOH  Kume  Island 
SG1-5-2 33  Comantella sp. cf. maculata  Echinodermata MeOH  Kume  Island 
SG1-9-2 57  Phanogenia gracilis  Echinodermata MeOH  Kume  Island 
SG1-12-2 39  Comanthus parvicirrus  Echinodermata MeOH  Kume  Island 
SG1-14-2 117  Comaster schlegelii  Echinodermata MeOH  Kume  Island 
SG1-15-2  26 Colobometridae  sp.  Echinodermata MeOH  Kume  Island 
SG1-16-2 66  Cenometra bella  Echinodermata MeOH  Kume  Island 
SG1-19-2 78  Comaster nobilis  Echinodermata MeOH  Kume  Island 
SG1-21-2 32  Oxycomanthus sp.  Echinodermata MeOH  Kume  Island 
SG1-23-1  -3  Alloeocomatella polycladia   Echinodermata EtOAc  Kume  Island Mar. Drugs 2012, 10               
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Table 1. Cont. 
SG1-24-1  24  Comanthus sp.  Echinodermata EtOAc  Kume  Island 
SG1-26-2 51  Oxycomanthus benetti  Echinodermata MeOH  Kume  Island 
SG1-28-2 38  Lamprometra palmata  Echinodermata MeOH  Kume  Island 
SG1-30-1  25  Colobometra perspinosa  Echinodermata EtOAc  Kume  Island 
SG1-31-1  26  Comanthus sp.  Echinodermata EtOAc  Kume  Island 
SG1-33-1 32  Basilometra boschmai  Echinodermata EtOAc  Kume  Island 
SG3-1 82  Stereonephthya sp.  Cnidaria EtOAc  Tokashiki  Island 
SG3-4 73  Dysidea cf. arenaria  Porifera EtOAc  Tokashiki  Island 
SG3-6 74  Stylotella sp.  Porifera EtOAc  Tokashiki  Island 
SG3-10 139  Epipolasis sp.  Porifera EtOAc  Tokashiki  Island 
SG3-11 97  Nephthea sp.  Cnidaria EtOAc  Tokashiki  Island 
SG3-21 106  Myrmekioderma sp.  Porifera EtOAc  Tokashiki  Island 
SG3-25 111  Pseudoceratina purpurea  Porifera EtOAc  Tokashiki  Island 
SG3-26 95  Leucetta sp.   Porifera EtOAc  Tokashiki  Island 
SG3-28 65  Lyngbya sp.  Cyanobacteria EtOAc  Tokashiki  Island 
SG3-29 61  Dysidea sp.  Porifera EtOAc  Tokashiki  Island 
Total number of marine organisms: 61; Marine organisms that strongly inhibit NS3 helicase activity (<30%) 
(boldface and underlined): 5; Extracts of organisms that exhibit intermediate inhibition of NS3 helicase activity 
(30%–60%) (underlined): 11; EtOAc: Ethyl acetate; MeOH: Methanol. 
Figure 1. Schematic representation of the PET assay system for unwinding activity of 
HCV NS3 helicase. The fluorescent dye (BODIPY FL) is attached to the cytosine at the  
5'-end of the fluorescent strand and quenched by the guanine base at the 3'-end of the 
complementary strand via photoinduced electron transfer. When the helicase unwinds the 
double-strand RNA substrate, the fluorescence of the dye emits bright light upon the 
release of the dye from the guanine base. The capture strand, which is complementary to 
the complementary strand, prevents the reannealing of the unwound duplex. 
 Mar. Drugs 2012, 10               
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Figure 2. Alloeocomatella polycladia belongs to a class of feather star (Echinodermata, 
Crinoidea). The ethyl acetate fraction prepared from the marine organism was designated 
SG1-23-1 in this study. 
 
Figure 3. Effect of SG1-23-1 on the unwinding activity of NS3 helicase. (A) NS3 helicase 
activity was measured by PET assay. The reactions were carried out in the absence or 
presence of SG1-23-1. Helicase activity in the absence of SG1-23-1 was defined as 100% 
helicase activity. Each value represents the mean of three independent reactions. Error bars 
indicate standard deviation. The data represent three independent experiments. (B) The 
unwinding activity of NS3 helicase was measured by RNA unwinding assay using 
radioisotope-labeled RNA. The heat-denatured single-strand RNA (26-mer) and the partial 
duplex RNA substrate were applied to lanes 1 and 2, respectively. The duplex RNA was 
reacted with NS3 (300 nM) in the presence of SG1-23-1 (lanes 4 to 9, 16 to 500 µg/mL). 
The resulting samples were subjected to native polyacrylamide gel electrophoresis. 
 
2.2. Effect of SG1-23-1 on HCV NS3 ATPase and RNA Binding Activities 
The unwinding ability of HCV helicase is dependent on ATP binding, ATP hydrolysis, and RNA 
binding [8,9]. We examined the effect of SG1-23-1 on the ATPase activity of NS3 helicase. The ratio 
of free phosphate (
32P-Pi) in ATP (
32P-ATP) was measured in the presence of SG1-23-1. The reaction Mar. Drugs 2012, 10               
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was carried out between 16 and 500 µg of SG1-23-1 per milliliter. ATPase activity was slightly 
increased at 16 µg SG1-23-1 per milliliter and slightly decreased at 500 µg SG1-23-1 per milliliter 
(Figure 4A). However, the helicase activity was decreased to less than 10% in the presence of 50 µg of 
SG1-23-1 per milliliter (Figure 3A,B). Next, we examined the effect of SG1-23-1 on the binding of 
NS3 helicase to single-strand RNA (ssRNA). A gel-mobility shift assay was employed to estimate the 
binding activity of NS3 to 21 mer of ssRNA. The binding of NS3 to ssRNA was inhibited with  
SG1-23-1 in a dose-dependent manner (Figure 4B). These results suggest that SG1-23-1 contains the 
compound that inhibits RNA binding to NS3 helicase. 
Figure 4. Effect of SG1-23-1 on ATPase and RNA-binding activities of NS3 helicase. 
(A) The reaction mixtures were incubated with [γ-
32P] ATP as described in Materials and 
Methods. The reaction mixtures were subjected to thin-layer chromatography. The start 
positions and migrated positions of ATP and free phosphoric acid are indicated as 
“Origin”, “
32P-ATP”, and “
32P-Pi”, respectively, on the left side of this figure. The data 
represent three independent experiments. (B) Gel mobility shift assay for RNA-binding 
activity of NS3 helicase. The reaction was carried out at the indicated concentration of 
SG1-23-1. The reaction mixture was subjected to gel mobility shift assay. The data 
represent three independent experiments. 
 
2.3. Effect of SG1-23-1 on HCV RNA Replication in HCV 1b Replicon Cells 
We investigated the effect of SG1-23-1 on both viral replication and growth of the replicon cell 
lines. The cell lines possess viral subgenomic RNAs derived from three genotype 1b strains (strains N [33], 
Con1 [34], and O [35]) or a full genomic RNA derived from the O strain [35]. Each cell line was 
treated with various concentrations of SG1-23-1. The treated cells were harvested 72 h post-treatment. 
Treatment with SG1-23-1 suppressed HCV RNA replications of all cell lines in a dose-dependent 
manner irrespectively of full- and sub-genome replicons; it exhibited no effect below 25 µg/mL and Mar. Drugs 2012, 10               
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little effect on cellular viability at the highest concentration, 50 µg/mL (Figure 5C,D). Both HCV NS3 
and NS5A were decreased at the protein level in a dose-dependent manner, corresponding to the viral 
replication, but beta-actin was not changed in the cell line harboring subgenome replicon RNA of the 
Con1 strain (Figure 5E). 
The inhibitory effect of SG1-23-1 on HCV replication is summarized in Table 2. The inhibitory 
effects on the HCV replication of the subgenome replicon derived from Con1, O, and N strains were 
22.9 ± 0.4, 19.9 ± 1.8, and 44.2 ± 1.5 µg/mL, respectively, as EC50; and 48.1 ± 1.5, 48.5 ± 0.3, and 
>50  µg/mL, respectively, as EC90. Treatment with SG1-23-1 inhibited the replication of the 
subgenome replicon of the O strain (EC50: 19.9 ± 1.8 µg/mL; EC90: 48.5 ± 0.3 µg/mL) at a more potent 
level than the replication of the full genomic replicon of the O strain (EC50: 39.5 ± 0.8 µg/mL; 
EC90: >50 µg/mL). When luciferase of firefly or Renilla was expressed under the control of the EF 
promoter, neither showed a significant change in activity in the presence of SG1-23-1 (Figure 5F). The 
replicon RNA of HCV is composed of the 5'-UTR of HCV, indicator genes (luciferase and   
drug-resistant genes), encephalomyocarditis virus (EMCV) IRES, the viral genes encoding complete or 
nonstructural proteins, and the 3'-UTR of HCV in that order [33–35]. The replicon RNA replicated 
autonomously in several HCV replication-permissive cell lines derived from several hepatoma cell 
lines. Nonstructural proteins in replicon cells were polycistronically translated through EMCV IRES. 
The cap-dependent translated mRNA, including Renilla luciferase, EMCV IRES, and the firefly 
luciferase/neomycin-resistant gene in that order, was constructed to examine the effect of the extract 
on EMCV-IRES-dependent translation (Figure 5G). When the expression of the mRNA was 
transcribed by an EF promoter of the transfected plasmid in the presence of SG1-23-1, the ratio of 
firefly luciferase activity to Renilla luciferase activity was not changed, suggesting that treatment with 
SG1-23-1 exhibited no effect on EMCV-IRES-dependent translation (Figure 5H). Thus, the inhibitory 
effect of SG1-23-1 on the luciferase activity must correspond to the replication efficiency of the 
replicon RNA but not to the inhibition of luciferase activity or the inhibition of EMCV-IRES-dependent 
translation. The inhibitory effect of the extract on the viral replication is similar to that of the extract on 
the helicase activity with respect to the values of IC50 and EC50 (Figure 3A and Table 2). These results 
suggest that treatment with SG1-23-1 inhibits HCV replication in a manner similar to that of the 
inhibitory effect on NS3 helicase activity. 
Figure 5. Effect of SG1-23-1 on viral replication in replicon cell lines. (A–D) Huh7 
Lunet/Con1 LUN Sb #26 (A), Huh7 rep Feo (B), Huh7#94/ORN3-5B#24 (C), and OR6 
(D) cell lines were incubated in medium containing various concentrations of SG1-23-1. 
Luciferase and cytotoxicity assays were carried out as described in Materials and Methods. 
Error bars indicate standard deviation. The data represent three independent experiments. 
(E) Protein extract was prepared from Huh7 Lunet/Con1 LUN Sb #26 cells treated for 72 h 
with an indicated concentration of SG1-23-1 and then was subjected to Western blotting 
using antibodies to NS3, NS5A, and beta-actin. (F) Huh7 cell line transfected with pEF 
Fluc IN vector or pEF Rluc IN was established in the presence of G418. Both cell lines 
were incubated without (control) and with 50 μg/mL SG1-23-1. Firefly or Renilla 
luciferase activity was measured 72 h post-treatment. Luciferase activity was normalized 
with protein concentration. Error bars indicate standard deviation. The data represent three Mar. Drugs 2012, 10               
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independent experiments. (G) Schematic structure of the plasmid, pEF Rluc EMCV IRES 
Feo. The bicistronic gene is transcribed under the control of elongation factor 1α (EF1α) 
promoter. The upstream cistron encoding Renilla luciferase (RLuc) is translated by a   
cap-dependent mechanism. The downstream cistron encodes the fusion protein (Feo), 
which consists of the firefly luciferase (Fluc) and neomycin phosphotransferase (Neo
r), and 
is translated under the control of the EMCV IRES. (H) Huh7 cell line transfected with pEF 
Rluc EMCV IRES Feo was established in the presence of G418. The cells were incubated 
for 72 h without (control) and with 50 µg/mL of SG1-23-1. Firefly or Renilla luciferase 
activity was measured by the method described in Materials and Methods and was 
normalized by the protein concentration. F/R: Relative ratio of Firefly luciferase activity to 
Renilla luciferase activity. F/R is presented as a percentage of the control condition. Error bars 
indicate standard deviation. The data represent three independent experiments. 
 Mar. Drugs 2012, 10               
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Table 2. Anti-HCV activity of SG1-23-1 in different replicon cell lines of genotype 1b. 
Replicon Cell Line  Virus Strain  EC50 
a EC90 
b CC50 
c 
   (Genotype  1b)  (µg/mL)  (µg/mL)  (µg/mL) 
Subgenome        
Huh7 Lunet/ 
Con1 LUN Sb #26   Con1  22.9 ± 0.4  48.1 ± 1.5  >50 
Huh7 rep Feo  N  44.2  ± 1.5  >50  >50 
Hu7#94/ORN3-5B#24  O  19.9 ± 1.8  48.8 ± 0.3  >50 
Full genome        
OR6  O  39.5 ± 0.8  >50  >50 
All data represent means ± standard deviation for three independent experiments; 
a Fifty percent effective 
concentration based on the inhibition of HCV replication; 
b Ninety percent effective concentration based on 
the inhibition of HCV replication; 
c Fifty percent cytotoxicity concentration based on the reduction of cell viability. 
2.4. Effect of SG1-23-1 on the Interferon (IFN) Signaling Pathway 
It has been reported that the HCV replication in cultured cells is potently inhibited by interferon   
(IFN) [36,37]. We examined whether or not treatment with SG1-23-1 induces interferon from replicon 
cells. The replicon cells were treated with various concentrations of interferon-alpha 2b or 50 µg of 
SG1-23-1 per milliliter. The treated cells were harvested at 72 h post-treatment. The interferon-inducible 
genes, MxA and 2',5'-OAS, were induced with IFN-alpha 2b but not with SG1-23-1 (Figure 6). These 
results suggest that the inhibitory effect of SG1-23-1 on the replication of the HCV replicon is 
independent of the IFN signaling pathway. 
Figure 6. Effect of SG1-23-1 on interferon signaling pathway. Huh7 Lunet/Con1 LUN Sb 
#26 cells were treated without (lane 1) or with 1, 10, or 100 U/mL IFNa-2b (lanes 2–4), 
and 50 µg/mL SG1-23-1 (lane 5) for 48 h. The mRNAs of MxA, 2',5'-OAS, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control were detected 
by reverse-transcription polymerase chain reaction (RT-PCR). Error bars indicate standard 
deviation. The data represent three independent experiments. 
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Treatment with SG1-23-1 suppressed the helicase activity of NS3 in a dose-dependent manner and 
exhibited an IC50 of 11.7 µg/mL. Interestingly, treatment with SG1-23-1 inhibited the RNA binding 
activity of the helicase but not the ATPase activity of NS3. Treatment with SG1-23-1 inhibited the 
luciferase activity corresponding to the HCV replication in the replicon cell lines, but not the 
enzymatic activity of luciferase or the translational activity of EMCV IRES, suggesting that treatment 
with SG1-23-1 decreases HCV replication. Figure 4 shows that the viral proteins NS3 and NS5A in 
replicon cells were decreased by treatment with SG1-23-1, supporting the notion that SG1-23-1 
inhibits HCV replication but not the enzymatic activity of luciferase. The inhibition of cell growth 
would not contribute to the inhibition of HCV replication by SG1-23-1 (Figure 3 and Table 2). 
Treatment with SG1-23-1 did not induce the interferon-stimulated genes in the replicon cell lines 
(Figure 6), suggesting that inhibition of HCV replication by treatment with SG1-23-1 is not due to 
interferon induction or interferon signaling. The extract SG1-23-1 inhibited the HCV replicon with an 
EC50 of 22 to 44 µg/mL, which is similar to the value of IC50. These results suggest that the anti-HCV 
compound(s) included in A. polycladia can suppress viral replication by inhibiting NS3 helicase activity. 
3. Experimental Section 
3.1. Preparation of Extracts from Marine Organisms 
All marine organisms used in this study were collected by hand during scuba diving off Shimoji, 
Okinawa, Chibishi, Kuro, Kume, and Tokashiki Islands in Okinawa Prefecture, Japan. In the case of 
OK-99-tagged extract, a specimen was soaked in ethanol. The ethanol-soluble fraction was 
concentrated, and the resulting aqueous material was suspended in ethyl acetate (EtOAc). The organic 
fraction was used for screening. 
Each specimen from Kume was soaked in ethanol. The ethanol-soluble fraction was concentrated. 
The resulting material was suspended in EtOAc. The EtOAc-soluble fraction was used for screening 
and tagged with SG1 and the last digit of “1”. The water layer was concentrated to dryness and 
suspended in methanol (MeOH). The MeOH-soluble fraction was used for screening and tagged with 
SG1 and the last digit of “2”. 
Each specimen from Tokashiki was extracted three times with acetone. After removal of acetone 
from the solution, the residual material was suspended in EtOAc. The EtOAc-soluble fraction was 
used for screening and tagged with SG3. 
All samples were dried and then solubilized in dimethyl sulfoxide (DMSO) before testing. 
3.2. High-Throughput Screening of NS3 Helicase Inhibitors 
A continuous fluorescence assay based on photoinduced electron transfer (PET) was described 
previously [38] and was slightly modified with regard to the reaction mixture. A schematic diagram of 
the PET assay for HCV NS3 helicase activity is shown in Figure 1. The double-strand RNA was 
prepared as a substrate by annealing, at a 1:2 molar ratio, a 5' BODIPY FL-labeled 37-mer   
(5'-CUAUUACCUCCACCCUCAUAACCUUUUUUUUUUUUUU-3') to a 23-mer (GGUUAUGAG 
GGUGGAGGUAAUAG). When unwound by HCV NS3 helicase, the unlabeled ssRNA was captured 
by a DNA capture strand (5'-CTATTACCTCCACCCTCATAACC-3'). A fluorescent-dye-labeled Mar. Drugs 2012, 10               
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oligonucleotide was purchased from J-Bio 21 Corporation. BODIPY FL was attached to the 5'-end via 
an aminohexylphosphate linker with a six-carbon spacer. Unlabeled oligonucleotides were purchased 
from Japan Bio Services Co., Ltd. The PET NS3 helicase assay was carried out in 22 µL of 25 mM 
MOPS-NaOH (pH 6.5) containing 3 mM MgCl2, 2 mM dithiothreitol (DTT), 4 U RNasin, 50 nM of 
the double-strand RNA described above, 100 nM DNA capture strand, 5 mM ATP, and the extract  
(25 µg/mL) and 240 nM HCV NS3 helicase. The reaction was started by the addition of HCV NS3 
helicase. The reaction mixture was incubated at 37 °C for 30 min. The fluorescence intensity was 
recorded every 5 s until 5 min post-reaction, and then every 30 s between 5 and 30 min post-reaction 
by using a LightCycler 1.5 (Roche Diagnostics, Tokyo, Japan). The initial reaction velocity was 
calculated and represented as NS3 helicase activity. 
3.3. ATPase Assay 
NS3 ATPase activity was determined by the method of Gallinari et al. [39] with slight 
modifications. The reaction was carried out at 37 °C for 10 min in 10 μL of the reaction mixture 
containing 25 mM MOPS-NaOH (pH 7.0), 1 mM DTT, 5 mM MgCl2, 5 mM CaCl2, 1 mM [γ-
32P] 
ATP (Muromachi, Tokyo, Japan), 300 nM NS3, and 0.1 μg poly (U) per microliter and an indicated 
concentration of SG1-23-1, and then was terminated by the addition of 15 microliters of 10 mM 
EDTA. Two microliters of the reaction mixture were spotted onto a polyethyleneimine cellulose sheet 
(Merck, Darmstadt, Germany) and then developed in 0.75 M LiCl/1 M formic acid solution at room 
temperature for 20 min. The sheet was air-dried completely and then exposed to an image plate. 
Radioactive bands were visualized with an Image Reader FLA-9000 and quantified by Multi Gauge V 
3.11 software (version 3.11; Fujifilm: Tokyo, Japan, 2008). 
3.4. RNA Helicase Assay 
NS3 RNA helicase assay was carried out by the method of Gallinari et al. [39] with slight 
modifications. The substrate for annealing two complementary RNA oligonucleotides,   
5'-AGAGAGAGAGGUUGAGAGAGAGAGAGUUUGAGAGAGAGAG-3' (40-mer, template strand) 
and 5'-CAAACUCUCUCUCUCUCAACAAAAAA-3' (26-mer, release strand) was purchased from 
Shanghai GenePharma Co., Ltd. The release strand was labeled at the 5'-end with [γ-
32P] ATP 
(Muromachi, Tokyo, Japan) using the T4 polynucleotide kinase (Toyobo, Osaka, Japan) at 37 °C for 
60 min and then purified by phenol chloroform extraction. The template and the labeled release strands 
were annealed at a molar ratio of 3:1 (template: release), denatured at 80 °C for 5 min, and slowly 
renatured at 23 °C for 30 min in an annealing buffer consisting of 20 mM Tris-HCl (pH 8), 0.5 M 
NaCl, and 1 mM EDTA. The partial duplex RNA substrate was purified on a G-50 micro column (GE 
Healthcare, Uppsala, Sweden) and stored at −20 °C in H2O containing 0.25 U of RNasin Plus 
(Promega, Madison, WI, USA) per microliter. 
SG1-23-1 extract was added at various concentrations to a helicase reaction mixture consisting of 
25 mM MOPS-NaOH (pH 7.0), 2.5 mM DTT, 2.5 U of RNasin Plus (Promega), 100 μg of BSA per 
milliliter, and 3 mM MgCl2. The mixture was supplemented with 300 nM NS3 protein and 5 fM  
32P-labeled partial duplex RNA substrate. It was then preincubated at 23 °C for 15 min. After adding 
ATP at a final concentration of 5 mM, the reaction mixture (20 µL) was incubated at 37 °C for 30 min Mar. Drugs 2012, 10               
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and stopped by adding 5 µL helicase termination buffer consisting of 0.1 M Tris-HCl (pH 7.5), 20 mM 
EDTA, 0.5% SDS, 0.1% Nonidet P-40, 0.1% bromophenol blue, 0.1% xylene cyanol, and 
25% glycerol. The terminated reaction mixture was subjected to native TBE 10% polyacrylamide gel 
electrophoresis. The radioactive RNAs in the gel were visualized with an Image Reader FLA-9000 
(Fujifilm) and quantified by Multi Gauge V 3.11 software. 
3.5. RNA Binding Assay 
RNA binding to NS3 helicase was analyzed by gel mobility shift assay [40]. First, let-7   
single-strand RNA (5'-UGAGGUAGUAGGUUGUAUAGU-3') was incubated with [γ-
32P] ATP 
(Muromachi, Tokyo, Japan) and T4 polynucleotide kinase (Toyobo) at 37 °C for 60 min for labeling at 
the 5'-end of the single-strand RNA. The reaction mixture was subjected to phenol chloroform 
extraction for purification of labeled RNA. The reaction was carried out at room temperature for 
15 min in 20 μL of the mixture consisting of 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM MgCl2, 
1 mM DTT, 1 unit of RNasin Plus (Promega) per microliter, 300 nM NS3, 5 fmol let-7-labeled 
ssRNA, and an indicated concentration of SG1-23-1. The reaction was stopped by adding an equal 
volume of dye solution consisting of 0.025% bromophenol blue, 10% glycerol, and 0.5× 
Tris/borate/EDTA (TBE). The resulting mixture was subjected to native 6% polyacrylamide gel 
electrophoresis (acrylamide: bis acrylamide = 19:1). The radioactive RNA was visualized with the 
Image Reader FLA-9000 and quantified by Multi Gauge V 3.11 software. 
3.6. Cell Lines 
The following Huh-7-derived cell lines used in this study were maintained in Dulbecco’s modified 
Eagle’s medium containing 10% fetal calf serum and 0.5 mg/mL G418: The Lunet/Con1 LUN Sb #26 
cell line, which harbors the subgenomic replicon RNA of the Con1 strain (genotype 1b) [34]; the 
Huh7/ORN3-5B #24 cell line, which harbors the subgenomic replicon RNA of the O strain (genotype 
1b) [35]; the Huh7 Rep Feo cell line, which harbors the subgenomic replicon RNA of the N strain 
(genotype 1b) [33]; and the OR6 cell line, which harbors the full genomic RNA of the O strain 
(genotype 1b) [35]. 
3.7. Determination of Luciferase Activity in HCV Replicon Cells 
HCV replicon cells were seeded at 2 × 10
4 cells per well in a 48-well plate 24 h before treatment. 
The extract SG1-23-1 was added to the culture medium at various concentrations. The treated cells 
were harvested 72 h post-treatment and lysed in cell culture lysis reagent (Promega) or Renilla 
luciferase assay lysis buffer (Promega). Luciferase activity in the harvested cells was estimated with a 
luciferase assay system (Promega) or a Renilla luciferase assay system (Promega). The resulting 
luminescence was detected by the Luminescencer-JNR AB-2100 (ATTO, Tokyo, Japan) and 
corresponded to the expression level of the HCV replicon. Mar. Drugs 2012, 10               
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3.8. Determination of Cytotoxicity in HCV Replicon Cells 
HCV replicon cells were seeded at a density of 1 × 10
4 cells per well in a 96-well plate and 
incubated at 37 °C for 24 h. The extract fraction of the sample code SG1-23-1 was added to the culture 
medium at various concentrations. These cells were treated with an indicated concentration of the 
extract fraction and then were harvested 72 h post-treatment. Cell viability was measured by 
dimethylthiazol carboxymethoxy-phenylsulfophenyl tetrazolium (MTS) assay using a CellTiter 96 
aqueous one-solution cell proliferation assay kit (Promega). 
3.9. Effects on Activities of Luciferase and Internal Ribosome Entry Site (IRES) 
The plasmid pEF Fluc IN and pEF Rluc EMCV IRES Feo were described previously [41]. The 
firefly luciferase gene was replaced with the Renilla luciferase gene in the plasmid pEF Fluc IN. The 
resulting plasmid was designated as pEF RlucIN in this study. The Huh7 cells were transfected with 
the pEF Fluc IN, pEF Rluc IN, or pEF Rluc EMCV IRES Feo and then were established in a medium 
containing 0.25 mg/mL G418 as described previously [41]. These cell lines were seeded at 2 × 10
4 
cells per well in a 48-well plate 24 h before treatment, treated with 50 μg/mL extract SG1-23-1, and 
then harvested at 72 h post-treatment. Activities of firefly and Renilla luciferases in pEF   
Rluc EMCV IRES Feo were measured with the dual luciferase reporter assay system (Promega). Total 
protein concentration was measured using the BCA Protein Assay Reagent Kit (Thermo Scientific, 
Rockford, IL, USA) to normalize luciferase activity. 
3.10. Western Blotting 
The cells were lysed in lysis buffer containing Cell Culture Lysis Reagent (Promega). The cell 
lysate was subjected to SDS-10% polyacrylamide gel (SDS-PAGE). The proteins in the gel were 
transferred onto a polyvinylidene fluoride (PVDF) membrane. The resulting membrane was incubated 
with the primary antibodies at 4 °C overnight and then was washed three times with PBS containing 
0.02% Tween 20 (PBS-T). The resulting membrane was reacted with a horseradish peroxidase-labeled 
anti-IgG antibody at room temperature for 2 h and then was washed three times with PBS-T. The 
reacted proteins were visualized with ImmunoStar LD (Wako Pure Chemical, Osaka, Japan). The 
antibodies to NS3 (Abcam, Cambridge, UK), NS5A (ViroGen, Watertown, MA, USA) and beta-actin 
were purchased from New England Biolabs (Beverly, MA, USA) and were used as the primary 
antibodies in this study. 
3.11. Reverse-Transcription Polymerase Chain Reaction (RT-PCR) 
The previously described method of RT-PCR [41] was slightly modified, as described below. Total 
RNA was isolated from cultured cells with the RNAqueous-4PCR kit (Ambion, Austin, TX, USA) and 
then was reverse-transcribed with a Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, 
USA). The transcribed mRNA was amplified with PCR using AmpliTaq Gold DNA polymerase 
(Applied Biosystems, Foster City, CA, USA) and an appropriate primer pair. Primer sequences 
targeting the genes encoding 2',5'-oligoadenylate synthetase (2',5'-OAS), myxovirus resistance protein 
A (MxA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were described previously [41]. Mar. Drugs 2012, 10               
 
759
4. Conclusions 
In conclusion, we showed that the ethyl acetate extract from Alloeocomatella polycladia 
significantly inhibits HCV replication by suppressing viral helicase activity. The purification of an 
inhibitory compound from the extract of Alloeocomatella polycladia will be required in order to 
improve the efficacy of chemical modification of the compound(s). 
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